US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
AU674492B2
(en)
|
1991-05-06 |
1997-01-02 |
United States of America, as represented by the Department of Health and Human Services, The |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
EP0940468A1
(fr)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Domaine variable d'un anticorps humanisé
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
RO118524B1
(ro)
|
1992-11-13 |
2003-06-30 |
Idec Pharmaceuticals Corp San |
Metoda pentru tratarea unei tulburari legata de celulele b
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
WO1996009380A1
(fr)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Procede d'accentuation de l'expression de molecules de classe i du complexe majeur d'histocompatibilite portant des peptides endogenes
|
ATE197765T1
(de)
|
1994-10-03 |
2000-12-15 |
Us Gov Health & Human Serv |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
ES2317646T3
(es)
|
1995-09-08 |
2009-04-16 |
Genzyme Corporation |
Vectores aav mejorados para terapia genica.
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
IL132560A0
(en)
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
EP1012236A1
(fr)
|
1997-08-15 |
2000-06-28 |
Rubicon Laboratory Inc. |
Retrovirus et vecteurs viraux
|
AU9397098A
(en)
|
1997-09-19 |
1999-04-12 |
Trustees Of The University Of Pennsylvania, The |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
ES2532910T3
(es)
|
1998-04-02 |
2015-04-01 |
Genentech, Inc. |
Variantes de anticuerpos y fragmentos de los mismos
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
TR200100373T2
(tr)
|
1998-08-07 |
2001-09-21 |
University Of Washington |
İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
|
DE69941905D1
(de)
|
1998-11-10 |
2010-02-25 |
Univ North Carolina |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
JP4827353B2
(ja)
|
1999-08-09 |
2011-11-30 |
ターゲティッド ジェネティクス コーポレイション |
鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
|
ES2290052T3
(es)
|
1999-09-21 |
2008-02-16 |
Genetics Institute, Llc |
Moleculas gl50 y usos para las mismas.
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
US6723316B2
(en)
|
1999-12-22 |
2004-04-20 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
|
EP1568779A1
(fr)
|
2000-01-21 |
2005-08-31 |
BioVex Limited |
souches du virus de l'herpes simplex pour le traitement oncolytique de cancers
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
AU2001273096B8
(en)
|
2000-06-28 |
2005-10-13 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 molecules: novel PD-1 ligands and uses therefor
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
IL157504A0
(en)
|
2001-05-11 |
2004-03-28 |
Wellstat Biologics Corp |
Oncolytic virus therapy
|
EP1411880B1
(fr)
|
2001-07-11 |
2018-04-25 |
University of Miami |
Vsv recombinant pour le traitement de cellules tumorales
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
US7247615B2
(en)
|
2001-11-30 |
2007-07-24 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen and uses therefor
|
US7235631B2
(en)
*
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
JP2005521398A
(ja)
|
2002-03-27 |
2005-07-21 |
ベイラー カレッジ オブ メディスン |
癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
RU2314830C2
(ru)
|
2002-06-21 |
2008-01-20 |
Веллстат Байолоджикс Корпорейшн |
Введение терапевтических вирусов
|
EP1391213A1
(fr)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
|
JP2005537802A
(ja)
|
2002-09-09 |
2005-12-15 |
ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション |
ラブドウイルスの組み換え型変異体及びその使用方法
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
HU227217B1
(en)
|
2002-12-16 |
2010-11-29 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
CA2520279C
(fr)
|
2003-03-27 |
2012-09-04 |
Ottawa Health Research Institute |
Virus mutant de la stomatite vesiculaire et son utilisation
|
ATE545699T1
(de)
|
2003-06-18 |
2012-03-15 |
Genelux Corp |
Modifizierte, rekombinante vacciniaviren und deren verwendungen
|
PL2292780T3
(pl)
|
2003-09-30 |
2018-05-30 |
The Trustees Of The University Of Pennsylvania |
Klady wirusów związanych z adenowirusami (AAV), sekwencje, wektory je zawierające i ich zastosowania
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
EP1694852B1
(fr)
|
2003-11-17 |
2010-10-13 |
Crusade Laboratories Limited |
Virus mutant de l'herpes simplex et son utilisation pour traiter le carcinome spinocellulaire
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
BRPI0417107A
(pt)
|
2003-12-19 |
2007-02-06 |
Genentech Inc |
fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
WO2005116224A2
(fr)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
WO2006002394A2
(fr)
|
2004-06-24 |
2006-01-05 |
New York University |
Souches de virus d'herpes simplex oncolytique non virulent modifiees pour bloquer la reponse hote innee
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトIgG4抗体
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
EP3050963B1
(fr)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
|
EP2963118B1
(fr)
|
2005-06-01 |
2017-08-09 |
California Institute of Technology |
Procede permettant le transfert cible de genes au moyen de vecteurs viraux
|
CA2613310C
(fr)
|
2005-06-23 |
2014-06-17 |
Baylor College Of Medicine |
Utilisation de l'herpes simplex virus type 2 mutant dans le traitement du cancer
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
PL2048955T3
(pl)
|
2006-07-21 |
2013-11-29 |
California Inst Of Techn |
Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
|
EP2415783B1
(fr)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Souches de virus de vaccin modifiées pour une utilisation pour le diagnostic et procédé thérapeutique
|
CA2672595A1
(fr)
|
2006-12-15 |
2008-06-19 |
Guy Hermans |
Sequences d'acides amines qui modulent l'interaction entre des cellules du systeme immunitaire
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
WO2008092117A2
(fr)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Nouvelles insertions, délétions et substitutions d'immunoglobulines
|
US8163292B2
(en)
|
2007-02-16 |
2012-04-24 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
WO2008156655A2
(fr)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Microorganismes pour une imagerie et/ou un traitement de tumeurs
|
CA2693707A1
(fr)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
Variants de b7-dc
|
CA2693623A1
(fr)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Utilisation d'un agent chimiotherapeutique dans la preparation d'un medicament pour traiter ou ameliorer un effet secondaire indesirable associe a une therapie virale oncolytique.
|
US20090136917A1
(en)
|
2007-10-25 |
2009-05-28 |
Szalay Aladar A |
Systems and methods for viral therapy
|
WO2009067800A1
(fr)
|
2007-11-27 |
2009-06-04 |
Viventia Biotech Inc. |
Anticorps dirigés contre un épitope associé au cancer de variant de nfkbib et ses utilisations
|
DK2222861T3
(en)
|
2007-12-11 |
2018-02-05 |
Univ North Carolina Chapel Hill |
POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
WO2009148488A2
(fr)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Utilisation de virus herpes oncolytiques pour tuer des cellules souches cancéreuses
|
CN104740610A
(zh)
|
2008-08-25 |
2015-07-01 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
EP3936122A1
(fr)
|
2008-11-24 |
2022-01-12 |
Massachusetts Institute Of Technology |
Procédés et compositions pour l'administration localisée d'un agent
|
WO2010080909A1
(fr)
|
2009-01-08 |
2010-07-15 |
Yale University |
Compositions et procédés d'utilisation de virus de la stomatite vésiculaire à action oncolytique
|
EP2283810A1
(fr)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Bactéries à administration orale en tant que véhicules pour l'administration systémique d'agents
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
BR112012001653A2
(pt)
|
2009-07-24 |
2016-11-08 |
Immune Design Corp |
partícula de vetor lentiviral, genoma de vetor lentiviral pseudotipado em um envelope, sistema de acondicionamento de vetor lentiviral para produzir uma partícula de vetor lentiviral pesudotipado, célula, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, métodos para fazer uma partícula de vetor lentiviral, e para distribuir partículas de vetor lentiviral para células invitro, e vacina terapêutica ou profilática
|
JP5883384B2
(ja)
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
CN102740887B
(zh)
|
2009-09-30 |
2015-04-15 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
EP2531216B1
(fr)
*
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos régule de façon critique l'expansion et la fonction des cellules inflammatoires humaines th17
|
TW201134481A
(en)
|
2010-03-12 |
2011-10-16 |
Abbott Biotherapeutics Corp |
CTLA4 proteins and their uses
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
CA2830254C
(fr)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Variants de fc
|
US9044420B2
(en)
|
2011-04-08 |
2015-06-02 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
WO2012149364A1
(fr)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Vaccins associés aux tumeurs et compositions pour l'interruption de l'immunosuppression dérivée de tumeurs destinées à être utilisées en combinaison avec une immunothérapie contre le cancer
|
US9428574B2
(en)
*
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
DK3357511T3
(da)
|
2011-06-30 |
2020-08-03 |
Genzyme Corp |
Inhibitorer af t-celleaktivering
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
PE20142451A1
(es)
|
2012-02-27 |
2015-02-04 |
Amunix Operating Inc |
Composiciones de conjugados de xten y metodos para realizar las mismas
|
EP3480316B1
(fr)
|
2012-03-30 |
2022-09-14 |
Immune Design Corp. |
Particules de vecteur lentiviral ameliorée en efficacite de la transduction de cellules exprimant dc-sign
|
CA2868748C
(fr)
|
2012-05-11 |
2022-07-26 |
Medimmune, Llc |
Variants de ctla-4
|
EP3508215A3
(fr)
*
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
WO2014198002A1
(fr)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
Bactérie produisant une protéine se liant à l'interféron et ses utilisations
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
WO2015103438A2
(fr)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
US20170196954A1
(en)
|
2014-07-15 |
2017-07-13 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
US10555981B2
(en)
|
2014-07-16 |
2020-02-11 |
Transgene S.A. |
Oncolytic virus for expression of immune checkpoint modulators
|
EP3699189A1
(fr)
|
2014-08-08 |
2020-08-26 |
The Board of Trustees of the Leland Stanford Junior University |
Agents pd-1 à haute affinité et procédés d'utilisation
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
WO2016073704A1
(fr)
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Composés immunothérapeutiques pour le cancer et les maladies auto-immunes
|
EP3020816A1
(fr)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Thérapie génique à médiation bactérienne
|
WO2016164428A1
(fr)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonistes de la voie de signalisation de mort cellulaire programmée 1 (pd-1) basés sur des récepteurs
|
PL3283508T3
(pl)
|
2015-04-17 |
2021-10-11 |
Alpine Immune Sciences, Inc. |
Białka immunomodulacyjne o dostrajalnym powinowactwie
|
US20180221508A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
CA2993429A1
(fr)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions et methodes pour therapies immuno-oncologiques
|
US20180256644A1
(en)
|
2015-09-14 |
2018-09-13 |
Alpine Immune Sciences, Inc. |
Tunable variant immunoglobulin superfamily domains and engineered cell therapy
|
PE20181044A1
(es)
|
2015-10-02 |
2018-07-03 |
Symphogen As |
Anticuerpos anti-pd-1 y composiciones
|
KR20190006495A
(ko)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
KR102536850B1
(ko)
*
|
2016-04-15 |
2023-05-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
JP2019522466A
(ja)
|
2016-05-18 |
2019-08-15 |
アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド |
変異pd−l1ポリペプチド、t細胞調節多量体ポリペプチド、及びそれらの使用方法
|
SG11201903407XA
(en)
|
2016-10-20 |
2019-05-30 |
Alpine Immune Sciences Inc |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
MA50404A
(fr)
|
2017-10-18 |
2020-08-26 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|